SCHEMBL6487252

SCHEMBL6487252

Cn1c(-c2ccncc2)c(/C=C/C(=O)O)c2cccnc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 1/20 0.43
FEN1 P39748 1/20 0.39
EGFR P00533 1/20 0.37
SRC P12931 1/20 0.37
PTGDR2 Q9Y5Y4 1/20 0.37
SLC6A2 P23975 2/20 0.36
MAPT P10636 2/20 0.36
POLB P06746 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
KDM5A P29375 2/20 0.36
KDM4C Q9H3R0 2/20 0.36
TEK Q02763 1/20 0.36
KDM4E B2RXH2 1/20 0.36
KDM6B O15054 1/20 0.36
KDM5B Q9UGL1 1/20 0.35
NAMPT P43490 1/20 0.35
ALDH1A1 P00352 2/20 0.35
NSD3 Q9BZ95 1/20 0.35
LMNA P02545 1/20 0.35
MAPK14 Q16539 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6487256 1.00 ABCB1 (0.43) ABCB1FEN1EGFRSRCPTGDR2
SCHEMBL6478016 0.93 ABCB1 (0.48) ABCB1FEN1EGFRSRCPTGDR2
SCHEMBL6478007 0.93 ABCB1 (0.48) ABCB1FEN1EGFRSRCPTGDR2
SCHEMBL6491313 0.88 ABCB1 (0.42) ABCB1FEN1EGFRSRCMAPT
SCHEMBL6478694 0.84 ABCB1 (0.45) ABCB1MAPTPOLBSMN1; SMN2KDM4E
SCHEMBL6478691 0.84 ABCB1 (0.45) ABCB1MAPTPOLBSMN1; SMN2KDM4E
SCHEMBL6479171 0.82 ABCB1 (0.51) ABCB1MAPTSMN1; SMN2KDM4EALDH1A1
SCHEMBL6479166 0.82 ABCB1 (0.51) ABCB1MAPTSMN1; SMN2KDM4EALDH1A1
SCHEMBL6477841 0.80 KDM4E (0.47) ABCB1MAPTPOLBSMN1; SMN2KDM4E
SCHEMBL6477843 0.80 KDM4E (0.47) ABCB1MAPTPOLBSMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014942-A1 Transforming growth factor inhibitor; controllign cell differentiation, cell proliferation NIPPON SHINYAKU CO., LTD. (JP) 2005-01-20 US disclosed
EP-1452525-A1 AMIDE DERIVATIVES AND DRUGS Nippon Shinyaku Co., Ltd. (JP) 2004-09-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014942-A1 Transforming growth factor inhibitor; controllign cell differentiation, cell proliferation TGFBR1, TGFBR2, TGFB1 ABCB1 2911/4885FEN1 4789/4885EGFR 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.